Michael Theisen Selected Research

Malaria Vaccines

1/2022	Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas.
4/2021	Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens.
1/2021	Extended follow-up of children in a phase2b trial of the GMZ2 malaria vaccine.
1/2021	Exploratory analysis of the effect of helminth infection on the immunogenicity and efficacy of the asexual blood-stage malaria vaccine candidate GMZ2.
8/2020	Evaluating the predictive performance of malaria antibodies and FCGR3B gene polymorphisms on Plasmodium falciparum infection outcome: a prospective cohort study.
1/2020	Effect of immune regulatory pathways after immunization with GMZ2 malaria vaccine candidate in healthy lifelong malaria-exposed adults.
1/2019	Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2.
1/2018	Plasmodium falciparum MSP3 Exists in a Complex on the Merozoite Surface and Generates Antibody Response during Natural Infection.
1/2017	Recognition of Plasmodium falciparum mature gametocyte-infected erythrocytes by antibodies of semi-immune adults and malaria-exposed children from Gabon.
1/2017	Naturally Acquired Antibodies Target the Glutamate-Rich Protein on Intact Merozoites and Predict Protection Against Febrile Malaria.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Theisen Research Topics

Disease

79	Malaria 06/2022 - 01/2004
32	Infections 06/2022 - 06/2003
5	Falciparum Malaria (Plasmodium falciparum Malaria) 01/2022 - 09/2004
5	Lyme Disease (Disease, Lyme) 12/2016 - 05/2002
4	Parasitemia 01/2020 - 02/2005
2	Coinfection 04/2021 - 01/2021
2	Parasitic Diseases (Parasitic Disease) 01/2017 - 10/2010
2	Human Influenza (Influenza) 12/2011 - 09/2008
2	Rabies (Hydrophobia) 01/2011 - 09/2010
2	Sickle Cell Trait 11/2007 - 02/2006
1	Cerebral Malaria 01/2022
1	COVID-19 12/2021
1	Hookworm Infections (Hookworm Infection) 04/2021
1	Rupture 01/2018
1	Bites and Stings (Sting) 09/2016
1	Fever (Fevers) 01/2016
1	Starvation 07/2012
1	Necrosis 08/2011
1	Crohn Disease (Crohn's Disease) 02/2011
1	Eosinophilia 01/2011
1	Anemia 01/2011
1	Asymptomatic Infections 02/2006
1	Communicable Diseases (Infectious Diseases) 12/2005

Drug/Important Bio-Agent (IBA)

43	VaccinesIBA 06/2022 - 01/2004
42	AntibodiesIBA 01/2022 - 06/2003
41	AntigensIBA 06/2022 - 02/2006
34	Immunoglobulin G (IgG)IBA 01/2022 - 01/2004
30	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2002
21	Malaria VaccinesIBA 01/2022 - 12/2005
14	Glutamic Acid (Glutamate)FDA Link 08/2020 - 01/2004
10	Membrane Proteins (Integral Membrane Proteins)IBA 08/2020 - 01/2004
6	Merozoite Surface Protein 1 (MSA1)IBA 06/2022 - 01/2004
5	Rabies Vaccines (Rabies Vaccine)FDA Link 01/2021 - 01/2011
4	1- acetyl- 1,2,3,3a,8,8a- hexahydro- 8a- hydroxy- 5- methoxypyrrolo(2,3- b)indole (CHMI)IBA 06/2022 - 01/2019
4	EpitopesIBA 01/2022 - 12/2016
4	Recombinant ProteinsIBA 01/2021 - 02/2006
4	Aluminum Hydroxide (Algeldrate)FDA Link 01/2021 - 01/2016
4	Antimalarials (Antimalarial Agents)IBA 01/2020 - 07/2012
4	ImmunosorbentsIBA 01/2020 - 06/2003
4	EnzymesIBA 01/2020 - 06/2003
4	Peptides (Polypeptides)IBA 02/2016 - 05/2002
4	Immunoglobulin M (IgM)IBA 02/2016 - 02/2008
3	aluminum sulfate (alum)IBA 01/2021 - 02/2005
3	Surface Antigens (Surface Antigen)IBA 06/2019 - 01/2004
3	Subunit VaccinesIBA 04/2016 - 12/2005
3	5- aminocarbonyl- 10,11- dihydro- 5H- dibenzo(a,d)cyclohepten- 5,10- imine (ADCI)IBA 04/2015 - 09/2004
3	Pharmaceutical PreparationsIBA 07/2012 - 11/2007
2	artemisinin (artemisinine)IBA 01/2022 - 01/2021
2	Immunoglobulins (Immunoglobulin)IBA 01/2022 - 08/2020
2	LigandsIBA 01/2018 - 06/2003
2	Complement System Proteins (Complement)IBA 02/2016 - 11/2009
2	Biomarkers (Surrogate Marker)IBA 01/2012 - 11/2007
1	GMZ2 vaccineIBA 01/2022
1	Albendazole (Albenza)FDA Link 04/2021
1	AnthelminticsIBA 04/2021
1	Blood Group Antigens (Blood Groups)IBA 08/2020
1	Cysteine (L-Cysteine)FDA Link 01/2020
1	Staphylococcal Protein A (Protein A)IBA 01/2020
1	Biological ProductsIBA 01/2020
1	EmulsionsIBA 01/2019
1	Protein Subunit VaccinesIBA 01/2019
1	Recombinant DNA (Recombinant DNA Research)IBA 01/2019
1	LipidsIBA 01/2019
1	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2018
1	1-oleoyl-2-stearoylphosphatidylcholineIBA 12/2016
1	OspC proteinIBA 12/2016
1	Amodiaquine (Camoquin)FDA Link 10/2015
1	pyrimethamine drug combination fanasil (Fansidar)FDA Link 10/2015
1	Fc gamma receptor IIAIBA 02/2015
1	IgG Receptors (Fc gamma RI)IBA 01/2014
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2014
1	Indicators and Reagents (Reagents)IBA 08/2013
1	Broadly Neutralizing AntibodiesIBA 02/2013
1	Coloring Agents (Dyes)IBA 07/2012
1	red dye CMXRosIBA 07/2012
1	Pyrimethamine (Daraprim)FDA Link 01/2012
1	VirosomesIBA 12/2011
1	DefensinsIBA 02/2011
1	Eosinophil Cationic ProteinIBA 01/2011
1	Immunoglobulin IsotypesIBA 01/2009
1	Liposomes (Liposome)IBA 09/2008
1	Oligonucleotide ProbesIBA 11/2007
1	beta-Globins (beta Globin)IBA 02/2006
1	Sickle HemoglobinIBA 02/2006
1	Hemoglobins (Hemoglobin)IBA 02/2006
1	B-Lymphocyte Epitopes (B-Cell Epitope)IBA 12/2005
1	Monatide (IMS 3015)IBA 02/2005
1	DNA (Deoxyribonucleic Acid)IBA 01/2005
1	Complement Factor H (Factor H)IBA 06/2003

Therapy/Procedure

1	Mosquito Nets 08/2020
1	Injections 01/2016
1	Chemoprevention 10/2015
1	Drug Therapy (Chemotherapy) 11/2007